Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background & Aims Liver fibrosis is the most worrisome feature of Nonalcoholic Steatohepatitis (NASH). Growing evidence supports a link between hepatocyte apoptosis and liver fibrogenesis. Our aim was to determine the therapeutic efficacy and safety of liver Bid, a key pro-apoptotic molecule, suppression using RNA interference (RNAi) for the treatment of fibrosis. Methods First, we optimized the delivery system for Bid siRNA in mice using ten different stealth RNAi siRNAs and two lipid formulations -Invivofectamine2.0 and a newly developed inviofectamine3.0 - that have been designed for high efficacy accumulation in the liver, assessed via real time PCR of Bid mRNA. Next, C57BL/6 mice were placed on a choline-deficient L-amino acid defined (CDAA) diet. After 19 wks of CDAA diet, a time-point that results in severe fibrotic-NASH, mice were injected with the selected Bid siRNA-Invivofectamine3.0 biweekly for three weeks. Additionally hepatocyte-specific Bid-deficient (BidΔhep) mice were placed on CDAA diet for 20 wks. Results A maximum Bid knockdown was achieved at 1.5 mg/kg siRNA with inviofectamine3.0, whereas it was at 7 mg/kg with Invivofectamine2.0. In NASH mice, after 3 wks of treatment, BID protein was reduced to 10% and this was associated with an improvement in liver fibrosis and inflammation associated with a marked reduction in TUNEL-positive cells, caspase 3 activation, and a reduction in mitochondrial BAX and BAK. BidΔhep mice showed similar protection from fibrotic changes. Conclusion Our data demonstrate that liver Bid suppression by RNAi technology, as well as hepatocyte-specific Bid-deficiency, improves liver fibrosis coupled with a reduction of inflammation in experimental NASH. These findings are consistent with existing evidence that hepatocyte apoptosis triggers HSC activation and liver fibrosis and suggest that Bid inhibition may be useful as an antifibrotic NASH therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · cited 1×
“Moreover, the liver is a particularly attractive organ for RNA-based therapy because siRNA penetrates the liver with high efficacy when administered via intravenous injection [30].”
BackgroundNecroptosis and its role in inflammation
Pasparakis, M., & Vandenabeele, P. (2015) · Nature · doi:10.1038/nature14191 · Cited by 2,148 · cited 1×
“Indeed, studies blocking caspases, in particular caspase 8 have suggested a potential switch into a death receptor-induced receptor protein kinases 1 and 3 (RIP1 and RIP3)-dependent necroptotic cell death [17,18].”
BackgroundLi, J., McQuade, T., Siemer, A. B., Napetschnig, J., Moriwaki, K., Hsiao, Y.-S., Damko, E., Moquin, D., Walz, T., McDermott, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.019 · Cited by 1,222 · cited 1×
“Indeed, studies blocking caspases, in particular caspase 8 have suggested a potential switch into a death receptor-induced receptor protein kinases 1 and 3 (RIP1 and RIP3)-dependent necroptotic cell death [17,18].”
BackgroundNon-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256 · cited 1×
“Growing evidence demonstrates that patients within the NAFLD spectrum who have progressed to non-alcoholic steatohepatitis (NASH), in particular NASH and fibrosis, are at a higher risk for disease-related morbidity and mortality [1–3].”
BackgroundThapaliya, S., Wree, A., Povero, D., Inzaugarat, M. E., Berk, M., Dixon, L., Papouchado, B. G., & Feldstein, A. E. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3167-6 · Cited by 162 · cited 1×
“Notably, attenuation of hepatocyte apoptosis by inhibition of caspases, in particular caspase 3 and 8, reduces fibrogenesis in animal models of NASH [7,8] thus establishing the proof of concept for anti-apoptotic NASH therapy.”
BackgroundSelf-citation
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Apoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 270
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“Of note, caspase 8 is crucial in linking the extrinsic and intrinsic apoptosis pathways 107 .”
Background
Metadata
- Authors
- Eguchi, A., De Mollerat Du Jeu, X., Johnson, C. D., Nektaria, A., & Feldstein, A. E.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 64
- Issue
- 3
- Pages
- 699-707
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2157548057
- Cited by
- 58
- References
- 5
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.